Lataa...
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma
Combining immunotherapy and BRAF targeted therapy may result in improved antitumor activity with the high response rates of targeted therapy and the durability of responses with immunotherapy. However, the first clinical trial testing the combination of the BRAF inhibitor vemurafenib and the CTLA-4...
Tallennettuna:
| Julkaisussa: | Sci Transl Med |
|---|---|
| Päätekijät: | , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4765379/ https://ncbi.nlm.nih.gov/pubmed/25787767 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.aaa4691 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|